Form 8-K

8-K — KORU Medical Systems, Inc.

Accession: 0001161697-26-000086

Filed: 2026-04-03

Period: 2026-03-30

CIK: 0000704440

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Entry into a Material Definitive Agreement

Item: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Item: Financial Statements and Exhibits

Documents

8-K — form_8-k.htm (Primary)

EX-10 — AMENDMENT NO. 3 TO LOAN & SECURITY AGREEMENT 03-30-2026 - HSBC VENTURES USA INC. (ex_10-1.htm)

GRAPHIC (hsbc_logo.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K CURRENT REPORT FOR 03-30-2026

8-K (Primary)

Filename: form_8-k.htm · Sequence: 1

Form 8-K

false

0000704440

2026-03-30

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities

Exchange Act of 1934

Date of Report (Date of earliest event reported) March 30, 2026

KORU Medical Systems, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-39086

13-3044880

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

100 Corporate Drive, Mahwah, NJ

07430

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area

code (845) 469-2042

_________________________________________________

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing

is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction

A.2. below):

[_] Written communications pursuant to

Rule 425 under the Securities Act (17 CFR 230.425)

[_] Soliciting material pursuant to Rule

14a-12 under the Exchange Act (17 CFR 240.14a-12)

[_] Pre-commencement communications pursuant

to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[_] Pre-commencement communications pursuant

to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of

the Act:

Title of each class

Trading symbol(s)

Name of each exchange on which registered

common stock, $0.01 par value

KRMD

The Nasdaq Stock Market

Indicate by check mark whether the registrant is an

emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2

of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company [_]

If an emerging growth company, indicate by check mark

if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards

provided pursuant to Section 13(a) of the Exchange Act. [_]

ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE

AGREEMENT.

Reference is made to the disclosure under Item 2.03

below which is hereby incorporated in this Item 1.01 by reference.

ITEM 2.03 CREATION OF A DIRECT FINANCIAL OBLIGATION OR AN

OBLIGATION UNDER AN OFF-BALANCE SHEET ARRANGEMENT OF A REGISTRANT.

On March 30, 2026, KORU Medical Systems, Inc. (the

“Company”) entered into an amendment (the “Amendment”) to its loan and security agreement, by and between the

Company and HSBC Ventures USA Inc., as lender, dated March 8, 2024, as amended (the “Loan and Security Agreement”), relating

to a revolving credit facility in an aggregate principal amount not to exceed $5,000,000 (the “Revolver”) and a term loan

facility in an aggregate principal amount not to exceed $5,000,000 (the “Term Loan” and collectively with the Revolver, the

“Credit Facility”). The Company has not drawn on the Credit Facility, and there is no obligation for the Company to do so

at any time.

The Amendment extends the maturity of the $5,000,000

Revolver from December 31, 2026 to March 30, 2028, and extends the interest-only period of the $5,000,000 Term Loan from September 30,

2026 to June 30, 2027 with a possible further extension to December 31, 2027 upon the achievement of certain EBITDA milestones as set

forth therein. The Term Loan maturity has been extended from December 1, 2028 to December 1, 2029. The Amendment lowers the interest rate

floor to 5.50% from 6.50% for the Revolver and the Term Loan. The Amendment removes the adjusted quick ratio covenant for both the Term

Loan and the Revolver. The adjusted quick ratio covenant for the Revolver has been replaced with a remaining months liquidity covenant

of at least twelve months, to be tested monthly beginning the first month the Revolver is drawn on; provided, however, the Company will

be in compliance if trailing three (3) month average Adjusted EBITDA (as defined in the Revolver) is positive.

The foregoing description of the Amendment is qualified

in its entirety by reference to the full text of the Amendment attached as Exhibit 10.1 to this Current Report on Form 8-K, which is incorporated

by reference into this Item 1.01.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits.

Exhibit No.

Description

10.1+

Amendment No. 3 to Loan and Security Agreement dated as of March 30, 2026

by and between KORU Medical Systems, Inc. and HSBC Ventures USA Inc.

104

Cover Page Interactive Data File (embedded within the inline XBRL document)

+ Schedules and exhibits have been omitted

pursuant to Item 601(b)(10) of Regulation S-K. The Registrant agrees to furnish supplementally a copy of any omitted schedule or

exhibit to the U.S. Securities and Exchange Commission upon request.

- 2 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange

Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

KORU Medical Systems, Inc.

(Registrant)

Date: April 3, 2026

By:

/s/ Thomas Adams

Thomas Adams

Chief Financial Officer

- 3 -

EX-10 — AMENDMENT NO. 3 TO LOAN & SECURITY AGREEMENT 03-30-2026 - HSBC VENTURES USA INC.

EX-10

Filename: ex_10-1.htm · Sequence: 2

Exhibit 10.1

AMENDMENT NO. 3 TO LOAN AND SECURITY AGREEMENT

This Amendment No. 3 to Loan and

Security Agreement (this “Amendment”) is entered into as of March 30, 2026 by and between (a) KORU MEDICAL SYSTEMS,

INC., a Delaware corporation (“Borrower”) and (b) HSBC Ventures USA Inc. (the “Bank”) with respect

to the Loan and Security Agreement dated as of March 8, 2024 by and between Borrower and Bank, as amended by that certain Amendment No.1

to Loan and Security Agreement dated as of March 31, 2025 by and between Borrower and Bank, as affected by that certain Waiver Agreement

dated as of May 6, 2025 by and between Borrower and Bank, and as further amended by that certain Amendment No. 2 to Loan and Security

Agreement dated as of December 24, 2025 by and between Borrower and Bank (as has been and as may be further amended from time to time,

the “Agreement”; capitalized terms used but not defined in this Amendment shall have the meaning given to such terms

in the Agreement).

1. Subject

to the satisfaction of the conditions precedent set forth in Section 3 below and effective as of the date hereof, the Agreement is hereby

amended as follows:

A. Section

1.1 (Definitions). The following terms and their respective definitions set forth in Section 1.1 of the Agreement are amended in their

entirety and replaced with the following:

“ “Draw

Period” is the period of time commencing upon the Effective Date and continuing through the earlier to occur of (a) the Draw

Period End Date or (b) an Event of Default.”

“ “Revolving

Line Maturity Date” is March 30, 2028.”

“ “Term

Loan Amortization Date” means July 1, 2027, which shall be extended to January 1, 2028 upon the occurrence of the EBITDA Milestone

Event.”

“ “Term

Loan Maturity Date” means December 1, 2029.”

B. Section

1.1 (Definitions). The following new terms and their respective definitions are inserted alphabetically in Section 1.1 of the Agreement:

“ “Adjusted

EBITDA” shall mean, calculated on a consolidated basis with respect to Borrower and its Subsidiaries, (a) Net Income, plus (b)

to the extent deducted in the calculation of Net Income (i) Interest Expense, (ii) depreciation expense and amortization expense, (iii)

income tax expense, and (iv) non- cash stock-based compensation expense.”

“ “Approved

Country” means Canada, France, Germany, Italy, Japan and the United Kingdom.”

“ “Draw

Period End Date” is June 30, 2027, which shall be extended to December 31, 2027 upon the occurrence of the EBITDA Milestone

Event.”

“ “EBITDA

Milestone Event” occurs if and when (if ever) Borrower has provided Bank with evidence, satisfactory to Bank in its sole and

absolute discretion, on or prior to June 30, 2027, that Borrower has achieved Adjusted EBITDA (calculated on a consolidated basis with

respect to Borrower and its Subsidiaries) in an amount greater than Zero Dollars ($0.00) for a period of two (2) consecutive fiscal quarters

ending after the Third Amendment Effective Date, but on or prior to June 30, 2027 (which period shall end no later than the last day of

the second (2nd) calendar quarter ending after the Third Amendment Effective Date).”

“ “Eligible

Foreign Accounts” means Accounts which are (a) denominated in Dollars, (b) billed from and/or payable to Borrower in the United

States, (c) owing from owing from an Account Debtor which has its principal place of business in an Approved Country and (d) otherwise

Eligible Accounts; provided that, in no event shall the aggregate Dollar Equivalent value of such Eligible Foreign Accounts included in

the Borrowing Base constitute more than Seven Hundred Fifty Thousand Dollars ($750,000.00).”

“ “Interest

Expense” means for any fiscal period, interest expense (whether cash or non-cash) determined in accordance with GAAP the relevant

period ending on such date, including, in any event, interest expense with respect to any Credit Extension and other Indebtedness of Borrower

and its Subsidiaries, including, without limitation or duplication, all commissions, discounts, or related amortization and other fees

and charges with respect to letters of credit and bankers’ acceptance financing and the net costs associated with interest rate

swap, cap, and similar arrangements, and the interest portion of any deferred payment obligation (including leases of all types).”

“ “Net

Income” means, as calculated on a consolidated basis with respect to Borrower and its Subsidiaries, for any period as at any

date of determination, the net profit (or loss), after provision for taxes, of Borrower and its Subsidiaries for such period taken as

a single accounting period.”

“ “Remaining

Months Liquidity” means, as of any date of determination, (a) the aggregate amount of Borrower’s unrestricted and unencumbered

cash and Cash Equivalents maintained with Bank and Bank’s Affiliates, divided by (b) expressed as a positive number, (i) Borrower

and its Subsidiaries’ Adjusted EBITDA for the most recent trailing three (3) month period, divided by (ii) three (3).”

“ “Repayment

Schedule” means the period of time equal to thirty (30) consecutive calendar months, which period of time shall be reduced to

twenty-four (24) consecutive calendar months upon the occurrence of the EBITDA Milestone Event.”

“ “Testing

Event” means the date on which Borrower has requested and Bank has made the initial Advance.”

“ “Third

Amendment Effective Date” is March 30, 2026.”

C. Section

1.1 (Definitions). Clause (e) of the definition of “Eligible Accounts” is amended in its entirety and replaced with the

following:

“ (e) Accounts

owing from an Account Debtor (i) which does not have its principal place of business in the United States or (ii) whose billing address

(as set forth

in the applicable invoice

for such Account) is not in the United States, unless in the case of both (i) and (ii), such Accounts are (x) Eligible Foreign Accounts

or (y) otherwise approved by Bank in writing;”

D. Section

1.1 (Definitions). The following terms and their respective definitions are deleted from Section 1.1 of the Agreement:

“ “Adjusted

Quick Ratio” is, calculated on a consolidated basis with respect to Borrower and its Subsidiaries, the ratio of (a) Quick Assets

to (b) Current Liabilities.”

“ “Current

Liabilities” are (a) all obligations and liabilities of Borrower and its Subsidiaries to Bank, plus (b) without duplication,

the aggregate amount of Borrower and its Subsidiaries’ Total Liabilities that mature within one (1) year.”

“ “Quick

Assets” is, on any date, Borrower and its Subsidiaries’ unrestricted and unencumbered cash and Cash Equivalents maintained

with Bank or Bank’s Affiliates, plus (ii) Eligible Accounts.”

“ “Testing

Date” means (a) prior to the Funding Date of the initial Advance, the last day of each calendar quarter and (b) on and after

the Funding Date of the initial Advance, the last day of each calendar month.”

“ “Total

Liabilities” is on any day, obligations that should, under GAAP, be classified as liabilities on Borrower and its Subsidiaries’

consolidated balance sheet, including all Indebtedness.”

E. Section

2.4 (Payment of Interest on the Credit Extensions). Section 2.4(a) of the Agreement is amended in its entirety and replaced with the

following:

“ (a) Interest

Rate.

(i) Advances.

Subject to Section 2.4(b), the principal amount outstanding under the Revolving Line shall accrue interest at a floating per annum rate

equal to the greater of (A) the Prime Rate and (B) five and one-half of one percent (5.50%), which interest, in each case, shall be payable

monthly in accordance with Section 2.4(d) below.

(ii) Term

Loan Advances. Subject to Section 2.4(b), the principal amount outstanding under each Term Loan Advance shall accrue interest

at a floating per annum rate equal to the greater of (A) the Prime Rate minus one-half of one percent (0.50%) and (B) five and one-half

of one percent (5.50%), which interest, in each case, shall be payable monthly in accordance with Section 2.4(d) below. Notwithstanding

any terms in this Agreement to the contrary, if at any time the interest rate applicable to any Term Loan Advance is less than zero percent

(0.0%), such interest rate shall be deemed to be zero percent (0.0%) for all purposes of this Agreement.”

F. Section

6.8 (Operating Accounts). Section 6.8(a) of the Agreement is amended in its entirety and replaced with the following:

“ (a) Each

Loan Party and each of their Subsidiaries shall maintain (i) at least seventy-five percent (75.0%) of its depository and operating accounts,

Cash Equivalents, and excess cash and (ii) upon the expiration of the Transition Period, the Collections

Account (as defined below),

with Bank or Bank’s Affiliates. In addition to the foregoing, Borrower shall, at all times, have unrestricted cash in on-balance

interest-bearing deposit accounts with Bank or Bank’s Affiliates in an aggregate amount equal to the lesser of (A) Five Million

Dollars ($5,000,000.00) and (B) one hundred percent (100.0%) of the Dollar Equivalent value of all account balances of each Loan Party

and each of their Subsidiaries held with Bank or Bank’s Affiliates. In addition to the foregoing, each Loan Party and each Subsidiary

shall obtain any business credit card and any letter of credit exclusively from Bank or an Affiliate of Bank. In addition, upon the expiration

of the Transition Period, Borrower shall direct Account Debtors to deliver and transmit all proceeds of Accounts into a collections account

of Borrower maintained with an Affiliate of Bank determined by Bank (the “Collections Account”) and all available funds in

the Collections Account shall be (i) when a Streamline Period is not in effect, (A) if there are Obligations under the Revolving Line

outstanding, applied to reduce the Obligations under the Revolving Line within seven (7) Business Days of receipt thereof or (B) if there

are no Obligations outstanding under the Revolving Line and no Event of Default has occurred, transferred to an account of Borrower maintained

with Bank or an Affiliate of Bank as determined by Bank within seven (7) Business Days of receipt thereof (or such shorter timeframe with

respect to (A) and (B) as Bank may agree to in writing in its sole discretion on a case-by-case basis upon receipt of a written request

from Borrower requesting that such proceeds be applied or remitted as the case may be as of an earlier date), or (ii) when a Streamline

Period is in effect, transferred on a daily basis to an account of Borrower maintained with Bank or an Affiliate of Bank.”

G. Section

6.9 (Financial Covenant – Remaining Months Liquidity). Section 6.9 of the Agreement is amended in its entirety and replaced

with the following:

“ 6.9 Financial

Covenant – Remaining Months Liquidity. Maintain, be tested as of the last day of the month in which the Testing Event occurs

and as of the last day of each calendar month thereafter, Remaining Months Liquidity greater than twelve (12). Notwithstanding the foregoing,

if, as of the last day of any month ending after the occurrence of the Testing Event, Borrower and its Subsidiaries’ trailing three

(3) month average Adjusted EBITDA is positive, then for such month, Borrower shall be deemed to be in compliance with the Remaining Months

Liquidity covenant set forth in this Section 6.9. ”

H. Section

9.1 (Rights and Remedies). Section 9.1(a) of the Agreement is amended in its entirety and replaced with the following:

“ (a) declare

all Obligations to be immediately due and payable (but if an Event of Default described in Section 8.5 occurs all Obligations shall be

automatically and immediately due and payable without any action by Bank) provided, however, that if an Event of Default occurs solely

pursuant to Section 6.9 hereof, Bank will not declare all Obligations under the Term Loan Advances immediately due and payable;”

I. Exhibit

B (Compliance Certificate). Schedule 3 to the Compliance Certificate appearing as Exhibit B to the Agreement is amended

in its entirety and replaced with the Schedule 3 to Compliance Certificate attached as Schedule 1 hereto.

J. Exhibit

B (Compliance Certificate). Schedule 6 to the Compliance Certificate appearing as Exhibit B to the Agreement is amended

in its entirety and replaced with the Schedule 6 to Compliance Certificate attached as Schedule 2 hereto.

2. As

amended hereby, the Agreement remains in full force and effect. Borrower represents and warrants that: (i) there are no Defaults or Events

of Default under the Agreement; (ii) there has been no Material Adverse Change since the Effective Date; (iii) all representations and

warranties of Borrower in the Agreement and all other documents executed in connection therewith are true and correct on the date hereof

in all material respects; provided, that such materiality qualifier shall not be applicable to any representations and warranties that

already are qualified or modified by materiality in the text thereof and provided, further that those representations and warranties expressly

referring to a specific date shall be true, accurate and complete in all material respects (or all respects, as applicable) as of such

date; (iv) the Agreement as amended hereby is legal and binding upon Borrower; and (v) Borrower is validly existing under the laws of

the State of its organization and has the requisite power and authority to execute this Amendment.

3. This

Amendment shall be effective upon satisfaction of all of the following conditions:

A. The

Bank shall have received counterparts of this Amendment executed on behalf of Borrower and the Bank.

B. The

representations and warranties of Borrower in this Amendment shall be true, accurate, and complete in all material respects on the date

hereof; provided, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified

or modified by materiality in the text thereof; and provided, further that those representations and warranties expressly referring to

a specific date shall be true, accurate and complete in all material respects (or all respects, as applicable) as of such date.

4. Borrower

hereby (a) reaffirms as of the date hereof each and every security interest and lien granted by Borrower in favor of the Bank and (b)

acknowledges that such security interests and liens continue in full force and effect.

5. This

Amendment shall be construed in accordance with and governed by the law of the State of New York, without regard to conflicts of law principles

except Title 14 of Article 5 of the New York General Obligations law.

6. This

Amendment may be executed in counterparts (and by different parties hereto on different counterparts), each of which shall constitute

an original, but all of which when taken together shall constitute a single contract. Delivery of any executed counterpart of a signature

page of this Amendment by email in .pdf format or any other electronic means that reproduces an image of the actual executed signature

page shall be effective as delivery of a manually executed counterpart of this Amendment.

7. The

parties agree and consent to the use of electronic signatures solely for the purpose of executing this Amendment or any related transactional

document (including any amendments thereto). Such electronic signatures shall be deemed to have the same full and binding effect as a

handwritten signature.

[signature page follows]

IN WITNESS WHEREOF, this Amendment

has been duly executed by the authorized representatives of the undersigned parties effective as of the date first written above.

BORROWER:

BANK:

KORU MEDICAL SYSTEMS, INC.

By: /s/ Thomas Adams

Name: Thomas Adams

Title: Chief Financial Officer

HSBC VENTURES USA INC.

By: /s/ Matthew Guarnaccia

Name: Matthew Guarnaccia

Title: Senior Vice President

Signature Page to Amendment No. 3 to Loan and Security Agreement

Schedule 1

SCHEDULE 3 TO COMPLIANCE CERTIFICATE

FINANCIAL COVENANT

I. Remaining

Months Liquidity (Section 6.9).

Required: Maintain, be tested as of the last

day of the month in which the Testing Even occurs and as of the last day of each calendar month thereafter, Remaining Months Liquidity

greater than twelve (12). Notwithstanding the foregoing, if, as of the last day of any month ending after the occurrence of the Testing

Event, Borrower and its Subsidiaries’ trailing three (3) month Adjusted EBITDA is positive, then for such month, Borrower shall

be deemed to be in compliance with the Remaining Months Liquidity covenant set forth in Section 6.9.

Actual:

Has Borrower requested and Bank made the initial Advance?

_______ Yes, continue below

_______ No, covenant not tested

Aggregate amount of Borrower’s unrestricted and unencumbered cash

and Cash Equivalents maintained with Bank and Bank’s Affiliates

$______

Borrower and its Subsidiaries’ Adjusted EBITDA for the most recent

trailing three (3) month period

$______

Line B divided by three (3)

$______

Remaining Months Liquidity (Line A divided by Line C)

_______

Is line B positive?

_______ Yes, in compliance

_______ No, continue below

Is line D greater than 12?

_______ Yes, in compliance

_______ No, not in compliance

Schedule 3 to Compliance Certificate

Schedule 2

SCHEDULE 6 TO COMPLIANCE CERTIFICATE

ACCOUNTS

Amount

of cash and Cash Equivalents maintained by each Loan Party and each of their Subsidiaries in all accounts with Bank or Bank’s

Affiliates at month end.

$_______________

Amount

of cash and Cash Equivalents maintained by each Loan Party and each of their Subsidiaries in accounts with a financial institution

other than Bank or Bank’s Affiliates at month end (complete a line below for each financial institution)

$_______________

Financial

Institution

Month

End Balance

Subject

to a

Control Agreement

in favor of Bank?

__________________________

$_______________

Yes No

__________________________

$_______________

Yes No

__________________________

$_______________

Yes No

__________________________

$_______________

Yes No

__________________________

$_______________

Yes No

Total

Cash (Line A plus the aggregate of Line B)

$_______________

Percentage

Maintained with Bank or Bank’s Affiliates (Line A divided by Line C - expressed as a percentage)

_______%

Line D equal or greater than seventy-five percent (75.0%)?

Yes,

in compliance _______

No, not

in compliance _______

Cash

maintained in on-balance sheet interest-bearing deposit accounts with Bank or Bank’s Affiliates

$_______________

Dollar

Equivalent value of all account balances of each Loan Party and each of its Subsidiaries with Bank or Bank’s Affiliates

$_______________

Lesser

of (i) Line G and (ii) Five Million Dollars ($5,000,000.00)

$_______________

Line F equal or greater than Line H?

Yes,

in compliance _______

No, not

in compliance _______

Schedule 6 to Compliance Certificate

GRAPHIC

Filename: hsbc_logo.jpg · Sequence: 3

Binary file (9548 bytes)

Download hsbc_logo.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Mar. 30, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Mar. 30, 2026

Entity File Number

001-39086

Entity Registrant Name

KORU Medical Systems, Inc.

Entity Central Index Key

0000704440

Entity Tax Identification Number

13-3044880

Entity Incorporation, State or Country Code

Entity Address, Address Line One

100 Corporate Drive

Entity Address, City or Town

Mahwah

Entity Address, State or Province

Entity Address, Postal Zip Code

07430

City Area Code

845

Local Phone Number

469-2042

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

common stock, $0.01 par value

Trading Symbol

KRMD

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration